Description

With the release of the new HBV guidelines, treatment eligibility broadens. This EASL Studio explores how to communicate these changes, support shared decision-making, ensure adherence, and engage patients in ongoing care and clinical trials.

Moderator: Ahmed Elsharkawy 

Faculty: Markus Cornberg, Sital Shah, Thomas Tu, Su Wang

This EASL Studio is supported by Aligos Therapeutics, Gilead Sciences Europe Ltd and GSK. EASL has received no input from Aligos Therapeutics, Gilead Sciences Europe Ltd, or GSK with regards to the content of this programme.

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Interested in chronic hepatitis B? Learn more with these resources provided by GSK.